Literature DB >> 21717886

A retrospective study comparing hypofractionated radiotherapy and conventional radiotherapy in postmastectomy breast cancer.

Attapol Pinitpatcharalert1, Imjai Chitapanarux, Juntima Euathrongchit, Ekkasit Tharavichitkul, Vimol Sukthomya, Vicharn Lorvidhaya.   

Abstract

BACKGROUND: The conventional radiotherapy (CRT) in postmastectomy breast cancer is 1.8-2.0 Gy daily for 25 fractions, while hypofractionated radiotherapy (HFRT) delivered dose in fewer fractions with larger radiation intensity. The present study compares the efficacy of HFRT and CRT. MATERIAL AND
METHOD: From 2004 to 2006, 215 patients were retrospectively reviewed. Sixty seven patients received CRT and 148 patients received HFRT (2.65 Gy in 16-18 fractions). Five-year locoregional control (LRC), disease free survival (DFS), overall survival (OS) and toxicities were analyzed.
RESULTS: Median follow-up was 39 months. Five-year LRC was 86.6% in CRT and 85.8% in HFRT (p = 0.852). Five-year DFS was 62.7% and 69.6% (p = 0.136) in CRTand HFRT respectively. Patients who received HFRT had significant increase in 5-year OS (62.7% and 73.0% (p = 0.048). No difference of toxicities including changes in chest wall appearance, skin fibrosis, brachial plexopathy, arm edema, pulmonary fibrosis, rib fractures and cardiovascular events was found between two groups.
CONCLUSION: HFRT is as effective as CRT in postmastectomy breast cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21717886

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  8 in total

1.  5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.

Authors:  Matthew M Poppe; Zeinab A Yehia; Christopher Baker; Sharad Goyal; Deborah Toppmeyer; Laurie Kirstein; Chunxia Chen; D F Moore; Bruce G Haffty; Atif J Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-11       Impact factor: 7.038

2.  Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.

Authors:  Sriram Venigalla; David M Guttmann; Varsha Jain; Sonam Sharma; Gary M Freedman; Jacob E Shabason
Journal:  Clin Breast Cancer       Date:  2018-02-21       Impact factor: 3.225

3.  Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer.

Authors:  Chokaew Tovanabutra; Kanyarat Katanyoo; Pichet Uber; Kittisak Chomprasert; Sitthi Sukauichai
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

4.  Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity.

Authors:  Imjai Chitapanarux; Pitchayaponne Klunklin; Attapol Pinitpatcharalert; Patumrat Sripan; Ekkasit Tharavichitkul; Wannapha Nobnop; Wimrak Onchan; Somvilai Chakrabandhu; Bongkot Jia-Mahasap; Juntima Euathrongchit; Yutthaphan Wannasopha; Tanop Srisuwan
Journal:  Radiat Oncol       Date:  2019-10-14       Impact factor: 3.481

5.  Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases.

Authors:  Mélanie Doré; Bruno Cutuli; Patrice Cellier; Loïc Campion; Magali Le Blanc
Journal:  Radiat Oncol       Date:  2015-08-04       Impact factor: 3.481

6.  A Comparative Study of Hypofractionated and Conventional Radiotherapy in Postmastectomy Breast Cancer Patients.

Authors:  Kartick Rastogi; Sandeep Jain; Aseem Rai Bhatnagar; Sandeep Bhaskar; Shivani Gupta; Neeraj Sharma
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Jan-Mar

7.  Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume.

Authors:  Arti Parekh; Avani D Dholakia; Daniel J Zabranksy; Fariba Asrari; Melissa Camp; Mehran Habibi; Richard Zellars; Jean L Wright
Journal:  Adv Radiat Oncol       Date:  2017-11-06

8.  Tolerance and outcome of hypofractionated post-mastectomy radiotherapy among elderly breast cancer patients in a specialized center in Nigeria.

Authors:  Usman Malami Aliyu; Awosan Kehinde
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.